Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Inflazome Ltd.. (11/19/18). "Press Release: Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept". Dublin & Cambridge.

Organisations Organisation Inflazome Ltd. (IE)
  Group Inflazome (Group)
  Organisation 2 Longitude Capital
Products Product NLRP3 inhibitor
  Product 2 venture capital
Index terms Index term Inflazome–SEVERAL: investment, 201811 financing round Series B €40m from Forbion + Longitude Capital + NVF + Fountain Healthcare Partners
  Index term 2 Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners
Persons Person Cooper, Matt (Inflazome 201811 CEO + Co-Founder)
  Person 2 Hirsch, David (Longitude Capital 201811 Managing Director + Founder)
     


> Financing led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating

> Funding to advance clinical trials of Inflazome’s pioneering orally-available NLRP3 inflammasome inhibitor compounds in several inflammatory diseases

> NLRP3 is associated with harmful inflammation in a broad range of serious medical conditions including Alzheimer’s, Parkinson’s, inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases


Inflazome, a pioneering inflammasome company developing small molecule drugs that block harmful inflammation, today announces the successful completion of a Series B financing round of €40 million ($46 million). The financing round was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating.

Clinical and scientific data indicates that the NLRP3 inflammasome, a compelling biological target that regulates our innate immune response, is overactive in a broad range of serious medical conditions driven by harmful inflammation. These include neurological disorders such as Alzheimer’s and Parkinson’s as well as inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases; conditions often inadequately treated by current therapies.

Inflazome is developing potent and selective small-molecule inhibitors of the NLRP3 inflammasome, to stop the cycle of chronic inflammation that drives such diseases. The Series B proceeds will be used to advance the Company’s first-in-class NLRP3 inflammasome inhibitors into multiple clinical trials in 2019, with next-generation compounds following thereafter.

Following the completion of the financing round, Dr Marco Boorsma, a General Partner at Forbion, and Dr David Hirsch, a Managing Director and Founder of Longitude Capital, have joined Inflazome’s Board of Directors.

Dr Matt Cooper, Co-Founder and CEO of Inflazome, commented: “We are very pleased to have secured a partnership with leading EU and US investors Forbion and Longitude and additional support from our founding investors, Novartis Venture Fund and Fountain Healthcare Partners. Forbion and Longitude have excellent track records of working closely with biotechs to drive R&D programs to successful clinical outcomes.”

Dr Marco Boorsma, General Partner at Forbion Capital Partners, commented: “Recognizing the important role of the inflammasome in many major diseases, we intensively screened the universe of companies active in this space. We decided to back Inflazome because of their leading position, deep understanding of inflammasome biology, foundational IP position and advanced and diversified pipeline of NLRP3 modulators. We were also highly impressed with the experience and knowledge of the Company’s Management Team and Board.”

Dr David Hirsch, Managing Director and Founder of Longitude Capital, added: “We’re excited by the potential of NLRP3 inhibitors and look forward to generating robust human proof of concept data with this financing.”

Inflazome Chairman, Dr Manus Rogan and Co-Founder and Managing Partner of Fountain Healthcare Partners, commented: “Due to the breadth of therapeutic applications, the market potential for a successful small molecule inhibitor of NLRP3 is clearly very significant. It has been exciting to have been involved in the Inflazome story since its inception and to follow our investment in one of the largest European venture capital backed financing rounds in the biotech sector this year.”


For details of our investors, please visit:

www.forbion.com
www.longitudecapital.com
www.fh-partners.com
www.nvfund.com


Contacts


Inflazome

Dr Jeremy Skillington | VP Business Development
E: j.skillington@inflazome.com
T: +353 1 687 5003

   
Record changed: 2018-11-22

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Inflazome (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top